On this page:Overview Publications Researchers Institutions Open access

ScholarIQanswers from OpenAlex

Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari

InstitutionResearch output, impact & collaborations

Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari is a institution indexed in ScholarIQ from OpenAlex.

What is known about Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari?

ScholarIQrecord summary

Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari is a research organisation in Bari, IT. OpenAlex records 2,432 works and 64,021 citations for it. 753 researchers list it as their most recent affiliation.

How many works does Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari have?

ScholarIQindexed works

Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari has 2,432 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

See the works listed for Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari →

How many citations does Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari have?

ScholarIQcitation count

Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari has 64,021 citations in the OpenAlex counts ScholarIQ stores.

See the listed works for Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari →

How many researchers are at Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari?

ScholarIQresearcher count

Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari has 753 researchers in the ScholarIQ index.

See the researchers listed on this page →

What is the average h-index at Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari?

ScholarIQavg h-index

Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari has an average h-index of 55.1 in OpenAlex.

Open the OpenAlex record →

What is the ROR of Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari?

ScholarIQror

The ROR for Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari is on the source record.

Open the ROR →

What is the OpenAlex record for Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari?

ScholarIQopenalex

The OpenAlex for Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari is on the source record.

Open the OpenAlex →

Who are the most-cited researchers behind Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari?

ScholarIQtop researchers by citations

Camillo Porta · Renal cell carcinoma treatment

987 works58,290 citations

Pellegrino Musto · Multiple Myeloma Research and Treatments

954 works29,710 citations

Giorgina Specchia · Acute Myeloid Leukemia Research

990 works24,395 citations

Francesco Giorgino · Diabetes Treatment and Management

640 works21,040 citations

Paolo Colonna · Cardiac Imaging and Diagnostics

266 works18,783 citations

What are the most-cited papers on Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari?

ScholarIQmost cited works

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Robert J. Motzer, Nizar M. Tannir, Ray McDermott, Osvaldo Arén Frontera, Bohuslav Melichar, Toni K. Choueiri, Elizabeth R. Plimack, Philippe Barthélémy, Camillo Porta, Saby George, Thomas Powles, Frede Donskov, Victoria Neiman, Christian Kollmannsberger, Pamela Salman, Howard Gurney, Robert D. Hawkins, Alain Ravaud, Marc‐Oliver Grimm, Sergio Bracarda, Carlos H. Barrios, Yoshihiko Tomita, Daniel Castellano, Brian I. Rini, Allen C. Chen, Sabeen Mekan, M. Brent McHenry, Megan Wind‐Rotolo, Justin Doan, Padmanee Sharma, Hans J. Hammers, Bernard Escudier

New England Journal of Medicine. 20184,691 CitationsOPEN ACCESS

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Robert J. Motzer, B. Yа. Alekseev, Sun Young Rha, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Grünwald, Thomas E. Hutson, Evgeny Kopyltsov, María José Méndez-Vidal, Vadim Kozlov, Anna Alyasova, Sung‐Hoo Hong, Anil Kapoor, Teresa Alonso Gordoa, Jaime R. Merchan, Eric Winquist, Pablo Maroto, Jeffrey C. Goh, Miso Kim, Howard Gurney, Vijay Patel, Avivit Peer, Giuseppe Procopio, Toshio Takagi, Bohuslav Melichar, Frédéric Rolland, Ugo De Giorgi, Shirley Wong, Jens Bedke, Manuela Schmidinger, Corina E. Dutcus, Alan D. Smith, Lea Dutta, Kalgi Mody, Rodolfo F. Perini, Dongyuan Xing, Toni K. Choueiri

New England Journal of Medicine. 20211,781 CitationsOPEN ACCESS

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Toni K. Choueiri, Thomas Powles, Mauricio Burotto, Bernard Escudier, María T. Bourlon, Bogdan Żurawski, Víctor Manuel Oyervides-Juárez, James J. Hsieh, Umberto Basso, Amishi Y. Shah, Cristina Suárez, Alketa Hamzaj, Jeffrey C. Goh, Carlos H. Barrios, Martin Eduardo Richardet, Camillo Porta, Rubén Dario Kowalyszyn, Juan P. Feregrino, Jakub Żołnierek, David Pook, Elizabeth R. Kessler, Yoshihiko Tomita, Ryuichi Mizuno, Jens Bedke, Joshua Zhang, Matthew Maurer, Burçin Şimşek, Flavia Ejzykowicz, Gisela Schwab, Andrea B. Apolo, Robert J. Motzer

New England Journal of Medicine. 20211,773 CitationsOPEN ACCESS

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial

Bernhard Ludvik, Francesco Giorgino, Esteban Jódar, Juan P. Frías, Laura Fernández Landó, Katelyn Brown, Ross Bray, Ángel Rodríguez

The Lancet. 2021621 Citations

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

Martin Gore, Cezary Szczylik, Camillo Porta, Sergio Bracarda, Georg A. Bjarnason, Stéphane Oudard, Subramanian Hariharan, Se‐Hoon Lee, John B.A.G. Haanen, Daniel Castellano, Eduard Vrdoljak, Patrick Schöffski, Paul N. Mainwaring, Alejandra Nieto, Jinyu Yuan, Ronald M. Bukowski

The Lancet Oncology. 2009591 Citations

How much of the research on Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari is open access?

ScholarIQopen access share

67%OPEN ACCESS

Gold

Green

Hybrid

Bronze

42%

Closed

33%